Leadership

Prof. Dr. Dolores J. Schendel

Chief Executive Officer (CEO) and Chief Scientific Officer (CSO)

Prof Dr Dolores Schendel joined Medigene as Chief Scientific Officer in 2014 with the acquisition of Trianta Immunotherapies (now Medigene Immunotherapies) where she was a majority founding member and has been Managing Director since 2013. She was appointed Chief Executive Officer with effect from February 2016. From 1998 - 2013, Prof Schendel was Director of the Institute of Molecular Immunology of the German Research Center for Environmental Health at the Helmholtz Center in Munich. Previous to this Prof Schendel served as a University Professor for Immunology at the Ludwig-Maximilian-University, focusing on human cellular immunology and T-cell responses within the field of oncology. Prof Schendel is the author of more than 200 scientific publications, has spent several decades as a scientific review board member in various research organizations such as the German Research Foundation, German Cancer Aid and the European Research Council among others. She is a recipient of the German Federal Order of Merit. Prof Schendel completed her PhD in Genetics at the University of Wisconsin, USA, followed by post-doctoral training in immunology at University College London, UK. She developed her interest in tumor immunology while working at the Sloan-Kettering Institute for Cancer Research in New York.

Dr. Thomas Taapken

Chief Financial Officer (CFO)

Dr. Thomas Taapken started as Medigene's CFO in January 2017. Before that, Dr. Taapken spent more than five years at Epigenomics AG, initially as CFO and subsequently, from October 2012, as its CEO/CFO. He then led the company’s efforts in gaining regulatory approval for the first blood-based molecular diagnostic cancer screening test by the FDA and oversaw its subsequent introduction into the US market. Before his time at Epigenomics, Dr. Taapken served as CFO at Biotie Therapies Corp. (now Acorda Therapeutics) and its predecessor companies for six years. His extensive international experience in the life sciences industry also includes over seven years as a venture capital investor at DVC Deutsche Venture Capital and San Francisco-based US venture capital firm Burrill & Company. Prior to that, he worked several years at Sanofi (originally Hoechst AG) in the United States and Germany, managing corporate venture capital activities, as well as in the areas of corporate & business development and research. Throughout his career, Dr. Taapken has been involved in numerous transactions spanning acquisitions, mergers and divestitures and helped to raise over EUR 100m through private and public offerings for those companies where he served in executive positions.

Essential positions:

  • Member of the Board of Immunic AG, Planegg/Martinsried, Germany
  • Member of the Board of Directors of SciBase AB, Stockholm, Sweden

Dr. Kai Pinkernell

Chief Medical Officer (CMO) and Chief Development Officer (CDO)

Dr. Kai Pinkernell is responsible for the clinical advancement of Medigene's immunotherapy platforms since February 2016. He has acquired long-term expertise in worldwide clinical development, clinical marketing and clinical sales as well as automation and GMP production of cellular therapies. Prior to joining Medigene, he held leading positions at Miltenyi Biotech GmbH, Bergisch Gladbach, Germany, most recently as Global Head of Clinical Business and Head of Clinical Development. Previously, Dr. Pinkernell was with Cytori Therapeutics Inc., San Diego, USA, as Senior Director of Regenerative Cell Technology. He studied medicine and received his MD from the Westfaelische-Wilhems University in Muenster, Germany. Furthermore, Dr. Pinkernell holds a Master of Business Administration from the Marshall School of Business at the University of Southern California, Los Angeles, USA.

Extended Management

Dr. Markus Dangl

Research & Pre-Clinical Development

Foto: Rolf Kalhammer

Dr. Rolf Kalhammer

Business Development

Gerard Luyben

Finance

Klaus Tressl

RA/ QA and QP

Dr. Thorsten Wöhl

CMC and Quality Control

Julia Hofmann

Public and Investor Relations

Dr. Slavoljub Milosevic

Technology Innovation

Marita Mogensen

Human Ressources and Business Operations

Christian Schmid

Legal Affairs

Dr. Dominik ter Meer

Intellectual Property